Skip to main content

Table 4 Adjusted association between hepatic adverse events and episodes groups in the PA arm

From: Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Parameters aOR (95% CI) with hepatic adverse events;
Elevated ALT
LR-p: 0.041
Elevated AST
LR-p: 0.262
Elevated total bilirubin
LR-p: <0.001
Episode groups    
 First treatment 1 1 1
 Retreatment 0.32 (0.14; 0.74) ** 0.59 (0.25; 1.41) 2.09 (1.01; 4.29) *
Age 0.98 (0.90; 1.05) 0.93 (0.83; 1.04) 1.12 (1.07; 1.17) ***
Sex    
 Female 1 1 1
 Male 1.47 (0.64; 3.38) 1.74 (0.69; 4.35) 1.10(0.57; 2.11)
  1. PA: pyronaridine-artesunate; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; LR-p: likelihood ratio test’s p-value; aOR: adjusted odds ratio; CI: Confidence interval;
  2. * p < 0.05; ** p < 0.01; *** p < 0.001